At 12 locations in Brazil between January 15 and July 6, 2022, a team led by Stanford University evaluated the use of the oral selective serotonin reuptake inhibitor fluvoxamine in combination with the inhaled corticosteroid budesonide in non-hospitalized adults with early symptoms of COVID-19 and at least one risk factor for severe disease. 

More patients in the treatment group than in the placebo group were either hospitalised within 28 days or evaluated in an emergency setting for COVID-19 for more than 6 hours. 

Weill Cornell Medicine researchers led a phase 2/3 platform trial assessing the safety and efficacy of amubarvimab plus romlusevimab. 

Compared to the placebo group, recipients of amubarvimab plus romlusevimab saw a considerably decreased risk of adverse events. 

The combination was equally effective against Delta and pre-Delta strains, according to a subgroup analysis of individuals possessing variation data, but the authors predicted that its efficacy against the now predominate Omicron variant would be restricted.